Alzheimer's Disease International

19 November 2025, The Hong Kong Alzheimer’s Disease Association (HKADA), ADI’s member association in Hong Kong will host the Asia Pacific Regional Members Meeting & Workshop, alongside a Public Symposium for the ‘New Era of Dementia Care’. The symposium will welcome leading professionals in healthcare and social sectors from over 17 countries and areas including China, Hong Kong, Australia, New Zealand, Philippines, India, Singapore, and Vietnam, etc that will share diverse perspectives and shape constructive dialogues towards building a compassionate and innovative future for dementia care. Speakers include : Paola Barbarino, CEO, ADI Alzheimer's Disease International Dr Jimmy Wu Yee-ming, Chairman, Hong Kong Alzheimer’s Disease Association Emily Ong Ong, Former Board Member ADI, Person Living with Cognitive Impairment Meera Pattabiraman, Vice-Chair, ADI Amalia Fonk -Utomo, Head of Accreditation, ADI Kaele Stokes, Executive Director of Services Advocacy and Research, Dementia Australia Stephen Chan, Director of Care Services, Dementia Singapore Veeda Michelle Anlacan, Associate Professor, College of Medicine, University of the Philippines Tuan Anh Nguyen, Upasana Baruah, Zara Page, National Ageing Research Institute (NARI), Australia Sarah Cullum, University of Auckland, New Zealand Thanh Binh Nguyen, National Geriatric Hospital, Vietnam Zihan He, University of Sydney, Australia; and many others For further details, please visit: https://lnkd.in/eKjDhh6R #HKADA #NewEraofDementiaCare

I will be speaking at the Alzheimer Iberoamerican (AIB)/ CEAFA ( the Spanish confederation of Alzheimers Associations) joint conference next week. If you are there come and say hallo! ( hoping for a a bit of sun, gloomy in London today!) Del 5 al 8 de noviembre de 2025, CEAFA, en colaboración con la Asociación de Familiares de Pacientes con Alzheimer de Ibiza y Formentera, acogerá el XI Congreso Nacional de Alzheimer y el XV Congreso Iberoamericano de Alzheimer. Bajo el lema «Rompiendo Barreras», el congreso aspira a ser un centro de conocimiento e intercambio entre profesionales médicos, investigadores, defensores y familiares. En consonancia con el tema del congreso, el Congreso Iberoamericano de Alzheimer de este año ofrece la oportunidad de trascender las barreras geográficas y unir a dos continentes, Europa y Latinoamérica, concentrando lo mejor del conocimiento internacional para brindar formación y estrategias a los participantes de todo el mundo. #RompiendoBarreras #CongresoIberoamericanoDeAlzheimer #CEAFA #AIB #CongresoDeDemencia From 5 to 8 November 2025, CEAFA, in collaboration with the Association of Relatives of Alzheimer’s Patients of Ibiza and Formentera, will host the 11th National Alzheimer’s Congress and the 15th Ibero-American Alzheimer’s Congress. Under the theme ‘Breaking Barriers’, the conference aims to be a hub of knowledge and exchanges between medical professionals, researchers, advocates and families. In line with the conference theme, this year’s Ibero-American Alzheimer’s Congress presents the opportunity to transcend geographical barriers and unite two continents of Europe and Latin America, concentrating the best of international knowledge to provide training and strategies for global attendees. #BreakingBarriers #IberoAmericanAlzheimerCongress #CEAFA #AIB #DementiaConference

ADI is delighted to announce our second annual End of Year Forecast, this year exploring the crucial topic of diagnostics and posing the question: are we ready for the diagnostic revolution? Taking place on 10 December, ADI CEO, Paola Barbarino, will be joined by special guest, renowned cognitive neurologist and Medical Director at the Banner Sun Health Research Institute, Dr Alireza Atri, to discuss insights into the global trends, challenges and opportunities shaping the Alzheimer’s diagnostic landscape. Register today: https://bit.ly/470vPl1 With the introduction of blood-based biomarkers, we must ask what the implications are for the diagnosis pathway. The potential for low-cost, less invasive and much earlier diagnosis is challenging our very definition of the condition and our response. Alongside the science, this raises ethical, psychological and emotional questions. How will healthcare systems respond in terms of education, training and preparedness? Will it revolutionise clinical trial participation? What are the implications for specialists? How must scanning technologies respond? and how must information provision, advice and support adapt to this new world? Be sure to register and join us for this livestreamed event as we seek to answer these crucial questions, as well as answer questions from the audience online and inside the room. #ADIForecast #AlzheimersTreatments #HealthWebinar #Dementia

As part of the closing session of Day One at the 12th Lausanne Dialogues (XII), ADI Deputy CEO Chris Lynch joined an expert panel on Policy Approaches to Addressing the Crisis Caused by Alzheimer’s. The discussion, moderated by Sofia Marchã, Senior Director and Head of European Public Policy at Biogen, examined the urgent policy measures needed to address the growing global impact of Alzheimer’s disease. Panel participants included Kavita V Nair, Professor of Neurology and Pharmacy at the University of Colorado Anschutz Medical Campus; Sue Peschin, President and Chief Executive Officer of the Alliance for Aging Research; and Chido Rwafa- Madzvamutse, Regional Advisor for Mental Health in the African Region at the World Health Organization. The session highlighted the pressing need for coordinated policy action, stronger health system preparedness and equitable access to treatment, support and care, particularly in low- and middle-income countries.. #LausanneXII

ADI CEO Paola Barbarino has opened the 12th Lausanne Dialogues (XII), an annual event supported by the CEOi - Global CEO Initiative on Alzheimer's Disease, in collaboration with Alzheimer’s Disease International, the OECD - OCDE and the World Economic Forum. The forum brings together industry leaders, clinicians, specialists, researchers, regulators and experts in multiple fields, debating, discussing and challenging this new era around diagnostics, treatment and health system readiness. “Over the past twelve years, we have had the privilege of co-hosting these discussions. Each dialogue has brought new experiences, deeper expertise and invaluable learnings for all of us - we are now at a critical time, with treatment and diagnostic breakthroughs. There is a sense of hope, with renewed confidence in research and groundbreaking innovation but this has to translate, at speed, into best practice.” She also highlighted the challenges posed by reduced choice and accessibility due to inconsistencies between regulators, as well as funding cuts to research and to the WHO. We look forward to sharing further insights from these two days of important dialogue #LausanneXII

Learn the latest on the dementia research and treatment landscape, as ADI invites a guest panel to shed light on this rapidly evolving sector. Join us for our webinar, ‘Dementia Research In Action: from trials to treatments’ at 1pm GMT on 13 November. Register today: https://bit.ly/43ijMNG In 2024, ADI hosted its inaugural End of Year Forecast, which marked a new era of dementia treatments by holding a livestreamed conversation with Professor Jeff Cummings, who shared his insights on the current pipeline of 127 drug treatments. This year, with a growing number of drug treatments currently in trials for Alzheimer’s disease, and many others addressing conditions such as Lewy Body Dementia and frontotemporal dementia, ADI welcomes our global audience to join us for this webinar, as ADI CEO Paola Barbarino hosts a timely discussion on new developments in the research field and the sharing of insights from those involved in designing, running and participating in clinical trials. We will look at the journey of new treatments, from regulator approval to clinic implementation, and explore the latest innovations in research. This webinar will also welcome insights from a person living with dementia who will discuss their involvement in treatment research and trials. Panellists to be announced soon.  #DementiaResearch #Dementia #DementiaTreatments

Brazil moves closer towards the development of its first National Dementia Plan! Last week saw the successful meeting of the 1st International Seminar on Public Policies in Dementia in #Brazil, organised by the ABRAz Associação Brasileira de Alzheimer (ABRAz) and PAHO/WHO, with the support of the Federação Brasileira das Associações de Alzheimer (FEBRAz), ADI’s member association in Brazil, a two-day seminar that brought together government officials, researchers, and civil society leaders to discuss the critical steps of securing the endorsement of the Ministry of Health so that the Plan can be formally developed, funded, and implemented across the country. Representing ADI, Diego Aguilar, Regional Director for the Americas, highlighted the opportunity to frame dementia as a key noncommunicable disease priority to strengthen public-health action and ensure continuity in Brazil’s next policy steps. ADI commends ABRAz, FEBRAz, Elaine Mateus, PAHO/WHO Brazil, and the Ministry of Health of Brazil for their continued leadership and collaboration towards the endorsement and development of Brazil’s National Dementia Plan. #DementiaPolicy #NationalDementiaPlan #Brasil

🇧🇷 Brazil takes another major step toward its first National Dementia Plan This week in Brasília, I joined government officials, researchers, and civil society leaders at the 1st International Seminar on Public Policies in Dementia, organized by ABRAz and PAHO/WHO, with the support of Federação Brasileira das Associações de Alzheimer, ADI’s member association in Brazil. Brazil has reached a key milestone through the recent 'pactuação' — a national consensus led by the Dementia Coaliton (CONADE) that sets the foundation for developing the country’s first National Dementia Plan, aligned with the WHO Global Action Plan on the Public Health Response to Dementia (2017–2031). What comes next is just as crucial: securing the endorsement of the Ministry of Health so the Plan can move from consensus to action — with funding, structure, and measurable results for families across the country. Representing Alzheimer's Disease International, I shared reflections on positioning dementia as a noncommunicable disorder priority to strengthen public-health responses and ensure continuity in national planning. Government representatives from Mexico and Chile also shared their experiences developing national dementia policies — showing how regional collaboration can accelerate progress for all. Brazil’s leadership and commitment are inspiring. Once the Plan is endorsed and developed, it will not only benefit millions of Brazilian families — it will also serve as a powerful model for the entire Americas region. Muito obrigado Elaine Mateus Celene Queiroz Pinheiro de Oliveira Eduardo Zimmer Leandro Minozzo Alexandre Padilha Mariangela Batista Galvao Simao Paulo Caramelli

ADI’s call for abstracts closes today, 15 October at 11:59 PM (BST). We are now in the final hours of our open call for abstract submissions. This is your final chance to send us your abstract and have the opportunity to showcase your solution to an international audience at the Global Conference of ADI, an event that welcomes over 1000 delegates from around the world. Join us from 14-16 April in Lyon, France as we bring together this truly global dementia community to share in the solutions for today and tomorrow, in partnership with France Alzheimer. Whether your solution focuses on dementia risk reduction, excellence in dementia care, innovative new assistive technologies, revolutionising the diagnostics pathway, or advocacy for the rights of people living with dementia and their carers, we want to hear from you! Choose from 48 abstract topics and submit your abstract today. https://lnkd.in/dVGfakuh #ADI2026 #DementiaConference #DementiaSolutions #SolutionsForTodayAndTomorrow #Dementia